Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study

Conclusion: Lower-dose decitabine demonstrated promising clinical response with acceptable toxicity profiles in patients with low- and intermediate 1-risk MDS. A higher response rate to decitabine was observed in patients with mutated genes. Therefore, lower-dose decitabine can be advocated for patients with low-risk MDS and mutated genes.

Source: Journal of Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Li Ye, Chen Mei, Yanling Ren, Xinping Zhou, Liya Ma, Weilai Xu, Juying Wei, Huifang Jiang, Liming Zhang, Hui Zeng, Hongyan Tong Tags: Research Paper Source Type: research